The effect of photodynamic therapy on tumor cell expression of major histocompatibility complex (MHC) class i and MHC class I-related molecules

Lasers in Surgery and Medicine

Volumn 44, Issue 1, 2012, Pages 60-68

  Belicha Villanueva, Alan ^a   Riddell, Jonah ^a   Bangia, Naveen ^a   Gollnick, Sandra O ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

MHC class I; MICA; NKG2D; PDT

Indexed keywords

2 (1 HEXYLOXYETHYL) 2 DEVINYLPYROPHEOPHORBIDE A; COMPLEMENTARY DNA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NATURAL KILLER CELL RECEPTOR NKG2D; PHOTOSENSITIZING AGENT; RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHOTODYNAMIC THERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; BLOTTING, WESTERN; COLONIC NEOPLASMS; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED BALB C; PHOTOCHEMOTHERAPY; REAL-TIME POLYMERASE CHAIN REACTION; RNA; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 84855962651     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.21160     Document Type: Article

References (45)

1. Henderson BW, Gollnick SO,. Mechanistic principles of photodynamic therapy. In:, Vo-Dinh T, editor. Biomedical photonics handbook. Boca Raton, FL: CRC Press; 2003. pp 36-1-36-27.
2. Brown SB, Brown EA, Walker I,. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004; 5: 497-508. (Pubitemid 39069400)
3. Dougherty TJ,. An update on photodynamic therapy applications. J Clin Laser Med Surg 2002; 20: 3-7. (Pubitemid 34174326)
4. Castano AP, Mroz P, Hamblin MR,. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 2006; 6: 535-545. (Pubitemid 43980542)
5. Gollnick SO, Brackett CM,. Enhancement of anti-tumor immunity by photodynamic therapy. Immunol Res 2010; 46: 216-226.
6. + T cells and dependent on natural killer cells. Br J Cancer 2007; 96: 1839-1848. (Pubitemid 46912014)
7. Blank M, Lavie G, Mandel M, Keisari Y,. Effects of photodynamic therapy with hypericin in mice bearing highly invasive solid tumors. Oncol Res 2001; 12: 409-418. (Pubitemid 33781093)
8. Castano AP, Gad R, Zahra T, Hamblin MR,. Specific anti-tumor immune response with photodynamic therapy mediated by benzoporphyrin derivative chlorin(e6). Jacques SL, Duncan DD, Kirkpatrick SJ, Kriete A, 4961, 1-9. The International Society for Optical Engineering, Proceedings of SPIE. Laser-Tissue Interaction XIV:Photochemical, Phototheramal and Photomechanical. Ref Type: Conference Proceeding. 2003.
9. Friedberg JS, Mick R, Stevenson JP, Zhu T, Busch TM, Shin D, Smith D, Culligan M, Dimofte A, Glatstein E, Hahn SM,. Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread. J Clin Oncol 2004; 22: 2192-2201. (Pubitemid 41095155)
10. Thong PS, Ong KW, Goh NS, Kho KW, Manivasager V, Bhuvaneswari R, Olivo M, Soo KC,. Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol 2007; 8: 950-952. (Pubitemid 47488070)
11. Thong PS, Olivo M, Kho KW, Bhuvaneswari R, Chin WW, Ong KW, Soo KC,. Immune response against angiosarcoma following lower fluence rate clinical photodynamic therapy. J Environ Pathol Toxicol Oncol 2008; 27: 35-42. (Pubitemid 351507421)
12. Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M, Stern PL, Moore JV, Corbitt G, Kitchener HC, Hampson IN,. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res 2001; 61: 192-196. (Pubitemid 32095717)
13. Kabingu E, Oseroff AR, Wilding GE, Gollnick SO,. Enhanced systemic immune reactivity to a basal cell carcinoma associated antigen following photodynamic therapy. Clin Cancer Res 2009; 15: 4460-4466.
14. Cronin SJ, Penninger JM,. From T-cell activation signals to signaling control of anti-cancer immunity. Immunol Rev 2007; 220: 151-168. (Pubitemid 350045570)
15. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S,. Functions of natural killer cells. Nat Immunol 2008; 9: 503-510. (Pubitemid 351560519)
16. Champsaur M, Lanier LL,. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010; 235: 267-285.
17. Eagle RA, Trowsdale J,. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007; 7: 737-744. (Pubitemid 47327391)
18. Stern-Ginossar N, Mandelboim O,. An integrated view of the regulation of NKG2D ligands. Immunology 2009; 128: 1-6.
19. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH,. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165-171. (Pubitemid 32867877)
20. Diefenbach A, Raulet DH,. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 2002; 188: 9-21. (Pubitemid 35398861)
21. Cerwenka A, Baron JL, Lanier LL,. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001; 98: 11521-11526. (Pubitemid 32928761)
22. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH,. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28: 571-580.
23. Nausch N, Cerwenka A,. NKG2D ligands in tumor immunity. Oncogene 2008; 27: 5944-5958.
24. Henderson BW, Bellnier DA, Greco WR, Sharma A, Pandey RK, Vaughan LA, Weishaupt KR, Dougherty TJ,. An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy. Cancer Res 1997; 57: 4000-4007. (Pubitemid 27427689)
25. Nava HR, Allamaneni SS, Dougherty TJ, Cooper MT, Tan W, Wilding G, Henderson BW,. Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus. Lasers Surg Med 2011; 43: 705-712.
26. Kousis PC, Henderson BW, Maier PG, Gollnick SO,. Photodynamic therapy (PDT) enhancement of anti-tumor immunity is regulated by neutrophils. Can Res 2007; 67: 10501-10510. (Pubitemid 350070826)
27. Tam YK, Maki G, Miyagawa B, Hennemann B, Tonn T, Klingemann HG,. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther 1999; 10: 1359-1373. (Pubitemid 29267590)
28. Tanabe M, Sekimata M, Ferrone S, Takiguchi M,. Structural and functional analysis of monomorphic determinants recognized by monoclonal antibodies reacting with the HLA class I alpha 3 domain. J Immunol 1992; 148: 3202-3209.
29. Stolina M, Sharma S, Huang M, Lin Y, Zhu L, Chen K, Lim K, Mao JT, Miller PW, Dubinett SM,. Tumor cyclooxygenase-dependent modulation of lymphocyte IL-10 production in murine lung cancer. Am Assoc Cancer Res 1997; 38: 121.
30. Korbelik M, Sun J,. Cancer treatment by photodynamic therapy combined with adoptive immunotherapy using genetically altered natural killer cell line. Int J Cancer 2001; 93: 269-274. (Pubitemid 32574284)
31. Henderson BW, Daroqui C, Tracy E, Vaughan LA, Loewen GM, Cooper MT, Baumann H,. Cross-linking of signal transducer and activator of transcription 3-A molecular marker for the photodynamic reaction in cells and tumors. Clin Cancer Res 2007; 13: 3156-3163. (Pubitemid 46944897)
32. Korbelik M,. PDT-associated host response and its role in the therapy outcome. Lasers Surg Med 2006; 38: 500-508.
33. Campoli M, Ferrone S,. HLA antigen changes in malignant cells: Epigenetic mechanisms and biologic significance. Oncogene 2008; 27: 5869-5885.
34. Peaper DR, Cresswell P,. Regulation of MHC class I assembly and peptide binding. Annu Rev Cell Dev Biol 2008; 24: 343-368.
35. Belicha-Villanueva A, McEvoy S, Cycon K, Ferrone S, Gollnick SO, Bangia N,. Differential contribution of TAP and tapasin to HLA class I antigen expression. Immunology 2008; 124: 112-120. (Pubitemid 351537578)
36. Grandea AG III, Van KL,. Tapasin: An ER chaperone that controls MHC class I assembly with peptide. Trends Immunol 2001; 22: 194-199.
37. Yamamoto K, Fujiyama Y, Andoh A, Bamba T, Okabe H,. Oxidative stress increases MICA and MICB gene expression in the human colon carcinoma cell line (CaCo-2). Biochim Biophys Acta 2001; 1526: 10-12. (Pubitemid 32245765)
38. Gollnick SO, Liu X, Owczarczak B, Musser DA, Henderson BW,. Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res 1997; 57: 3904-3909. (Pubitemid 27427673)
39. Park MJ, Bae JH, Chung JS, Kim SH, Kang CD,. Induction of NKG2D ligands and increased sensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrin-based photodynamic therapy. Immunol Invest 2011; 40: 367-382.
40. Venkataraman GM, Suciu D, Groh V, Boss JM, Spies T,. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J Immunol 2007; 178: 961-969. (Pubitemid 46095169)
41. MacDonald IJ, Morgan J, Bellnier DA, Paszkiewicz G, Whitaker JE, Litchfield DJ, Dougherty TJ,. Subcellular localization patterns and their relationship to photodynamic activity of pyropheophorbide-a derivatives. Photochem Photobiol 1999; 70: 789-797. (Pubitemid 129555013)
42. Kepp O, Galluzzi L, Kroemer G,. Mitochondrial control of the NLRP3 inflammasome. Nat Immunol 2011; 12: 199-200.
43. Bahram S, Bresnahan M, Geraghty DE, Spies T,. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci USA 1994; 91: 6259-6263. (Pubitemid 24200639)
44. King DE, Jiang H, Simkin G, Obochi M, Levy JG, Hunt DWC,. Photodynamic alteration of the surface receptor expression pattern of murine splenic dendritic cells. Scand J Immunol 1999; 49: 184-192. (Pubitemid 29096315)
45. Blom DJ, Schuitmaker HJ, De Waard-Siebinga I, Dubbelman TM, Jager MJ,. Decreased expression of HLA class I on ocular melanoma cells following in vitro photodynamic therapy. Cancer Lett 1997; 112: 239-243. (Pubitemid 27104301)